Research and Development Expense

The treatment of research and development expense splits between US and international standards. Under GAAP, all R&D costs are expensed in the period incurred. Under IFRS, research is expensed, but development costs meeting a stringent six-criterion test are capitalized as intangible-assets. This divergence can shift reported earnings by millions and complicates comparisons between US and non-US companies.

The GAAP rule: immediate expense

In the US, Statement of Financial Accounting Standards (SFAS) 2, later codified under ASC 730-10, mandates that research and development costs be expensed as incurred. There is no capitalization, no asset deferral, no amortization. The rationale is both conservative and practical: the future benefit of R&D is uncertain, the cost of tracking projects is high, and expensing immediately ensures that reported earnings are not inflated by speculative asset values.

This approach applies to all R&D spending: salaries of scientists and engineers, laboratory materials, depreciation of R&D equipment, purchased research, patent costs, and pre-development testing. Even successful R&D is expensed. A pharmaceutical company that spends $2 billion developing a blockbuster drug and ultimately brings it to market records the entire $2 billion as period expense, not as an asset on the balance sheet. Reported earnings are lower and more volatile than under capitalization, but creditors and investors see what they got: immediate, verifiable cash outflow, not a speculative future benefit.

The IFRS approach: conditional capitalization

International Accounting Standard 38 distinguishes between research and development. Research is defined broadly as investigation undertaken to acquire new knowledge; it is always expensed. Development is the application of research findings or knowledge to produce new or improved products or processes; it may be capitalized if six criteria are met.

The six criteria are: (1) technical feasibility of the intangible asset is demonstrated; (2) the entity intends to complete the asset and use or sell it; (3) the entity is able to use or sell the asset; (4) the asset will generate probable future economic benefit; (5) resources to complete development are available; and (6) the entity can reliably measure the development cost. These conditions must all be satisfied. If even one is not met, development costs are expensed.

Most companies find that criterion four—probable future economic benefit—is the gating test. For early-stage biotech or hardware startups, this is nearly impossible to satisfy. A company developing a speculative technology with uncertain market adoption will not meet the test. A company with pilot customers or a signed pre-launch contract can. Development costs that clear the six-criterion gate are capitalized as an intangible asset and amortized over the period of expected benefit, typically 5 to 10 years for software or processes, longer for pharmaceuticals under regulatory exclusivity.

Why the divergence matters

The gap between GAAP and IFRS can be striking. A software company developing a major new platform might capitalize €50 million of development costs under IFRS, adding it to the balance sheet and spreading the expense over 7 years; under US GAAP, the entire €50 million would be expensed immediately, depressing reported earnings by that amount in the development year. Over time, the IFRS company’s balance sheet grows with intangible assets while its earnings are smoothed; the GAAP company’s balance sheet is lighter but earnings are more volatile.

This divergence is particularly acute in tech, biotech, and specialty chemicals, where R&D is a core operating expense. A pharmaceutical company reporting under IFRS can capitalize development costs for Phase III trial programs meeting the criteria; a US pharmaceutical company cannot. This does not mean the IFRS company is more profitable; it means the profit is deferred and the asset value is more speculative. Analysts comparing US and European biotech firms must adjust for this methodological gap.

Capitalization thresholds in practice

When development costs are capitalized under IFRS, the company must document each project meeting the six criteria. Auditors scrutinize the probable economic benefit assessment closely. A company cannot assume a market will exist; it needs evidence—a customer commitment, a pilot program, or a binding development agreement. If a development project fails or is abandoned before completion, capitalized costs are written off immediately as an impairment loss, and that loss appears in the income statement, creating a one-time hit.

The standard is principles-based, not rules-based, which means companies have judgment and auditors have discretion. A biotech company in early Phase II is unlikely to meet criterion four; a company with a Phase III contract in hand typically does. The line is often blurry, and different auditors may reach different conclusions. Companies in regulated industries (pharmaceuticals, medical devices) can cite FDA approval and market exclusivity as evidence of probable benefit, strengthening the capitalization case.

Software development under IAS 38 vs. ASC 730

Software development is a sub-category where the divergence is most visible. Under IFRS, software development costs incurred after technical feasibility is proven—typically when the design phase is complete and development begins—are capitalized. Under US GAAP, all software R&D is expensed, though costs of software-development-cost-capitalization for internal-use software are governed by separate guidance (ASC 350-40) and can be capitalized. This separate track exists because internal-use software is less speculative than research and development; the company controls the specification and benefit is more certain.

The tax treatment wild card

Many jurisdictions offer R&D tax credits—cash rebates or credits against tax liability for qualifying R&D spend. These credits are available regardless of whether the cost is capitalized or expensed for book purposes; they depend only on the substance of the work, not the accounting treatment. This adds a third incentive layer: book treatment (GAAP vs. IFRS), tax treatment (jurisdiction-specific R&D credit rules), and cash treatment (when cash is paid) can all diverge. A company may expense costs for GAAP, capitalize under IFRS for purposes of IFRS reporting, and claim an R&D credit for tax, all simultaneously and all consistently with law.

See also